MI.UN-T 0.33 DRVN-Q 0 SWIM-Q 0 TOL-N -0.07 NOG-N -0.26 CPA-N -0.03 PBH-T 1.49
Teva Pharmaceutical (TEVA-N)

Teva Pharmaceutical (TEVA-N)

0.00
-0.00 (0.00%)
66 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0

Related posts

Nervous markets await Nvidia
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Jan 05, 2024

It's cheap and has momentum, but that's all it has now. It never grabbed him.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$11.330

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Aug 04, 2023

Massive share price appreciation not sustainable. 
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time. 

Lorne SteinbergLorne Steinberg
Unknown
Unlock Rating
$9.745

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

Teva Pharmaceutical(TEVA-N)

Jan 06, 2023
Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.
David FingoldDavid Fingold
Unknown
Unlock Rating
$10.520

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Mar 17, 2022
He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.
Brian Acker, CABrian Acker, CA
No
Unlock Rating
$7.805

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Nov 11, 2021
Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.
Lorne SteinbergLorne Steinberg
No
Unlock Rating
$9.545

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Apr 15, 2021
Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.
Christine PooleChristine Poole
No
Unlock Rating
$10.845

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Oct 19, 2020

Doesn't offer growth. The stock is weak and will stay weak.

Jim Cramer - Mad MoneyJim Cramer - Mad Money
Unknown
Unlock Rating
$9.290

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Teva Pharmaceutical(TEVA-N)

Feb 27, 2020
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$12.210

Stock price when the opinion was issued

biotechnology pharmaceutical
HOLD

Teva Pharmaceutical(TEVA-N)

Nov 28, 2019
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
Bruce MurrayBruce Murray
No
Unlock Rating
$10.450

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Aug 15, 2019
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
Lorne SteinbergLorne Steinberg
No
Unlock Rating
$6.160

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Jul 17, 2019
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
Paul MacDonaldPaul MacDonald
No
Unlock Rating
$8.110

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Jul 03, 2019
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
Norman LevineNorman Levine
No
Unlock Rating
$9.600

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

Jul 02, 2019
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
Paul Harris, CFAPaul Harris, CFA
Unknown
Unlock Rating
$9.430

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA-N)

May 22, 2019
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
Norman LevineNorman Levine
No
Unlock Rating
$11.540

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Teva Pharmaceutical(TEVA-N)

May 03, 2019
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
Paul MacDonaldPaul MacDonald
No
Unlock Rating
$15.180

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 15 of 272 entries
Next PageNext Page

Teva Pharmaceutical(TEVA-N) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Teva Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Teva Pharmaceutical(TEVA-N) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a OTC stock, trading under the symbol TEVA-N on the (). It is usually referred to as or TEVA-N

Is Teva Pharmaceutical a buy or a sell?

In the last year, there was no coverage of Teva Pharmaceutical published on Stockchase.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by on . Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Teva Pharmaceutical worth watching?

0 stock analysts on Stockchase covered Teva Pharmaceutical In the last year. It is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On , Teva Pharmaceutical (TEVA-N) stock closed at a price of $.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MGA-N -0.17$41.45
AJG-N 2.78$320.88
MCB-T 0.07$4.42
MHC.U-… -0.05$18.25
CAR.UN… 0.53$45

Today's Top Picks

MI.UN-… 0.33$14.63
DRVN-Q 0$18.07
SWIM-Q 0$7.03
TOL-N -0.07$117.72
NOG-N -0.26$29.54

Popular Articles

Latest Sell Signals

AX.UN-… 0.19$7.77
SRU.UN… 0.36$25.9
CRR.UN… 0.12$15.04
AP.UN-… 0.66$17.97
CPX-T -0.19$54.45

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

John Ewing

John Ewing

Ewing Morris Investment Partners

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rebecca Teltscher

Rebecca Teltscher

Newhaven Asset Management

Rick Rule

Rick Rule

Rule Investment Media

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica